SEQUENTIAL METHOTREXATE, 5-FLUOROURACIL (5-FU), AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU ALONE FOR ADVANCED COLORECTAL-CANCER - A MULTIINSTITUTIONAL RANDOMIZED TRIAL

被引:0
|
作者
ABAD, A
GARCIA, P
GRAVALOS, C
TUSQUETS, I
FONT, A
PEREZ, G
CORTESFUNES, H
FABREGAT, X
BARNADAS, A
ROSELL, R
机构
[1] HOSP GEN GREGORIO MARANON,DEPT MED ONCOL,MADRID,SPAIN
[2] HOSP 12 OCTUBRE,DEPT MED ONCOL,E-28041 MADRID,SPAIN
[3] HOSP DEL MAR,DEPT MED ONCOL,BARCELONA,SPAIN
关键词
FLUOROURACIL; 5-FU; BIOCHEMICAL MODULATION; COLORECTAL CANCER;
D O I
10.1002/1097-0142(19950315)75:6<1238::AID-CNCR2820750605>3.0.CO;2-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The primary objective of this study was to compare the single-biochemical modulation of 5-fluorouracil (5-FU) and leucovorin with that of the double-biochemical modulation of methotrexate and leucovorin. Because of the Martin et al. study in which an experimental model showed similar effects of 5-FU at maximum tolerated doses to the modulation with leucovorin at standard doses, a third treatment arm of 5-FU alone was also studied. Methods. A randomized trial was performed using a 500-mg/m(2) intravenous (i.v,) 1-hour infusion of methotrexate, and 12 hours later, a 600-mg/m(2) i.v. bolus of 5-FU plus a 200-mg/m(2) i.v. 1-hour infusion of leucovorin (MFL) every 2 weeks versus 5-FU plus leucovorin at an equal dose and schedule (FL), versus a 1200-mg/m(2) i.v dose of 5-FU every 2 weeks. Of 186 patients included in the study, 178 were evaluable. Results. In a preliminary analysis with 94 evaluable patients, two significant statistical differences were shown. First, the toxicity rate of the 5-FU-alone (F) treatment arm was higher than that of the other arms (MFL vs. F, P = 0.0002; FL vs. F, P = 0.00001). Second, the median survival was worse in the F treatment arm with a rate of 12.6 months for the MFL and FL arms and 7.5 months for the F arm (P < 0.05). Considering these results, the F treatment arm was discontinued. The final results included 70 evaluable patients for MFL and 74 patients for FL. No difference was found in the distribution of prognostic factors. The response rates were 25.7% for MFL (95% CI, 16-37.5) and 14.8% for FL (95% CI, 7.6-25), (P = 0.1). The median survival was 14.3 months for patients treated with MFL and 12.3 months for those treated with FL. The hematologic toxicity was mild, with no grade 3/4 leukopenia in either treatment arm. The major nonhematologic toxicity in the MFL and FL treatment arms was ocular; nongrade 3/4 diarrhea also was observed. Conclusions. The results of MFL double-biochemical modulation failed to show a significant statistical difference from that of single-biochemical modulation for this dose and schedule.
引用
收藏
页码:1238 / 1244
页数:7
相关论文
共 50 条
  • [21] Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer
    Tsavaris, N
    Kosmas, C
    Gennatas, K
    Vadiaka, M
    Skopelitis, E
    Xila, V
    Rokana, S
    Margaris, E
    Zografos, G
    Papastratis, G
    Kouraklis, G
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (04) : 406 - 411
  • [22] Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan
    Tai, CJ
    Liu, JH
    Chen, WS
    Lin, JK
    Wang, WS
    Yen, CC
    Chiou, TJ
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) : 136 - 140
  • [23] HIGH-DOSE 5-FLUOROURACIL (5-FU) AND FOLINIC ACID IN ADVANCED COLORECTAL SITES OF DISEASE CANCER RESISTANT TO STANDARD-DOSE LOCAL 5-FU TREATMENT - RESULTS OF A LIVER PHASE-II STUDY
    JAGER, E
    KLEIN, O
    WACHTER, B
    MULLER, B
    BRAUN, U
    KNUTH, A
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) : 1717 - 1717
  • [24] SUMMARY OF THE AIO 7/90 PROTOCOL - RANDOMIZED PHASE-222 STUDY WITH ELF (ETOPOSIDE/5-FU/LEUCOVORIN) VERSUS 5-FU INFUSION/CISPLATIN VERSUS FAMTX (METHOTREXATE/5-FU/ADRIAMYCIN) IN ADVANCED STOMACH-CANCER
    WILS, J
    WILKE, H
    ROUGIER, P
    PREUSSER, P
    LACAVE, A
    ONKOLOGIE, 1992, 15 (01): : 71 - 72
  • [25] A COMPARISON OF 5-FLUOROURACIL(5-FU) LEUCOVORIN WITH OTHER CURRENT CHEMOTHERAPEUTIC REGIMENS IN THE TREATMENT OF METASTASIZING COLORECTAL-CANCER
    BAUR, M
    SCHLAPPACK, O
    HAVELEC, L
    MADER, R
    MAROSI, C
    SCHEITHAUER, W
    DITTRICH, C
    WIENER KLINISCHE WOCHENSCHRIFT, 1991, 103 (11) : 332 - 339
  • [26] HIGH-DOSE MTX/5-FU AND ADRIAMYCIN FOR GASTRIC-CANCER
    KLEIN, HO
    WICKRAMANAYAKE, PD
    DIETERLE, F
    MOHR, R
    OERKERMANN, H
    GROSS, R
    SEMINARS IN ONCOLOGY, 1983, 10 (02) : 29 - 31
  • [27] Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV)
    Lin, YC
    Liu, HE
    Wang, CH
    Wang, HM
    Yang, TS
    Liau, CT
    Chen, JS
    ANTICANCER RESEARCH, 1999, 19 (6C) : 5615 - 5620
  • [28] CLINICAL-EXPERIENCE WITH 5-FLUOROURACIL (5-FU) AND HIGH-DOSE FOLINIC ACID IN SOLID TUMORS
    MARINI, G
    ZANIBONI, A
    GORNI, F
    MARPICATI, P
    MONTINI, E
    SIMONCINI, E
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1987, 13 (06) : 373 - 376
  • [29] UFT/leucovorin vs 5-FU/leucovorin in colon cancer
    Smith, RE
    Lembersky, BC
    Wieand, HS
    Colangelo, L
    Mamounas, EP
    ONCOLOGY-NEW YORK, 2000, 14 (10): : 24 - 27
  • [30] HIGH-DOSE INTERMITTENT IV 5-FU AND MELPHALAN IN ADVANCED COLORECTAL-CARCINOMA
    GOUGH, IR
    FURNIVAL, CM
    CANCER TREATMENT REPORTS, 1983, 67 (06): : 595 - 596